Oscar Health stock rose nearly 2% on Tuesday despite missing analyst estimates on revenue ($2.8B vs. $3.1B expected) and posting a deeper net loss ($1.24 per share vs. $0.89 expected). The stock gained on bullish full-year 2026 guidance projecting $18.7-19B in revenue and $250-450M in operating earnings, along with strong membership growth exceeding 2 million members.

Oscar Health reported Q4 2025 revenue of $2.81B, missing estimates of $3.12B, with a loss of $1.24 per share. The company faced challenges from higher medical costs and morbidity in 2025 but projects a significant turnaround in 2026, guiding for $18.7-19B in revenue and $250-450M in operating earnings. Membership grew to 2.04M, and the company secured a $475M credit facility to strengthen its balance sheet.

Oscar Health, a technology-focused health insurer, is gaining significant market share in the ACA marketplace with 2 million members and deploying AI tools like its Oswell chatbot. Despite short-term headwinds from rising healthcare costs and expiring subsidies, the company is raising prices 28% for 2026 and is positioned for profitability, with a $12 billion revenue projection against a sub-$4 billion market cap.

Oscar Health Inc. (NYSE:OSCR) is experiencing declining momentum with its Momentum score dropping from 62.07 to 13.22 in one week, amid a 19.14% monthly decline. The health insurance stock has underperformed with only 7% year-to-date gains. Health insurance stocks face pressure due to uncertainties regarding Affordable Care Act subsidy extensions. Despite current weakness, analysts expect a turnaround in 2026, with Piper Sandler upgrading the stock to 'Overweight' with a $25 price target, implying 72% upside potential.

The market is showing signs of rotation toward undervalued non-AI stocks. The article discusses two undervalued companies that have experienced significant pullbacks in 2025 and are expected to show fundamental improvements in 2026.

Oscar Health is planning significant price increases in 2026 to offset higher healthcare service costs after underestimating customer service expenses in 2025.

Oscar Health faces challenges in 2025 with rising medical costs and expiring healthcare subsidies, but is positioned to return to profitability in 2026 through strategic plan pricing increases and technology-driven customer experience.

The article compares SoundHound AI with Nelnet and Oscar Health, arguing that these two companies have better earnings potential and are currently undervalued compared to SoundHound AI, which has a high market valuation but is losing money.

Glynn Capital Management reduced its stake in Oscar Health by selling 153,753 shares, but remains the largest shareholder. Oscar Health is rebuilding its insurance strategy and technology platform, showing signs of stabilization and potential long-term growth.

The White House is preparing to introduce a healthcare framework to extend Affordable Care Act subsidies, proposing a two-year extension with updated eligibility limits and measures to control premium increases affecting approximately 22 million Americans.

Oscar Health experienced a significant stock decline, but the author remains optimistic about its long-term potential and will maintain his current investment position.

Healthcare insurance provider Centene reported strong Q3 2025 earnings, beating consensus estimates with adjusted earnings of 50 cents per share. The company raised its full-year guidance and saw significant growth in Marketplace and Medicare enrollment.